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The G2019S mutation in the leucine-rich repeat kinase 2 (LRRK2) gene is the most common genetic cause of Parkinson’s disease (PD),
accounting for a significant proportion of both autosomal dominant familial and sporadic PD cases. Our aim in the present study is to
generate a mammalian model of mutant G2019S LRRK2 pathogenesis, which reproduces the robust nigral neurodegeneration charac-
teristic of PD. We developed adenoviral vectors to drive neuron-specific expression of full-length wild-type or mutant G2019S human
LRRK2 in the nigrostriatal system of adult rats. Wild-type LRRK2 did not induce any significant neuronal loss. In contrast, under the
same conditions and levels of expression, G2019Smutant LRRK2 causes a progressive degeneration of nigral dopaminergic neurons. Our
data provide a novel rat model of PD, based on a prevalent genetic cause, that reproduces a cardinal feature of the disease within a rapid
time frame suitable for testing of neuroprotective strategies.
Introduction
Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene have
emerged as the most common genetic determinant of Parkin-
son’s disease (PD) (Berg et al., 2005; Healy et al., 2008). Themost
prevalent mutation in LRRK2, G2019S, accounts for 5–6% of
autosomal-dominant familial and 1–2%of sporadic PD cases (Di
Fonzo et al., 2005; Gilks et al., 2005; Healy et al., 2008). The
G2019S variant is found at frequencies as high as 40% of both
familial and sporadic cases in specific populations such as Ash-
kenazi Jews (Ozelius et al., 2006) and North African Arabs
(Lesage et al., 2006). Patients harboring theG2019Smutation are
clinically indistinguishable from sporadic PD cases (Healy et
al., 2008). The vast majority of LRRK2-linked cases display neu-
ropathology typical of sporadic PD, characterized mainly by a
dramatic loss of dopaminergic neurons in the substantia nigra
pars compacta (SNpc) (Giasson et al., 2006; Ross et al., 2006). A
G2019S LRRK2mammalian model, which recapitulates the hall-
mark nigral neurodegeneration, should therefore provide a pow-
erful platform for evaluation of disease-modifying therapies
aimed at both familial and sporadic PD patients. Transgenic
mouse models developed to date, however, fail to achieve signif-
icant levels of LRRK2 overexpression in the SNpc and conse-
quently do not display dopaminergic neuronal loss (Li et al.,
2009, 2010; Melrose et al., 2010). Alternative gene delivery tools
are therefore required to reproduce the progressive degeneration
of nigral neurons associated with the G2019S mutation in PD.
Materials andMethods
Adenoviral vector construction and virus production
Second-generation E1, E3, E2a-deleted recombinant human serotype 5
adenoviruses (rAd)were generated (Zhou andBeaudet, 2000; Young and
Neher, 2009). A modified version of the pDC511 shuttle plasmid (Mi-
crobix) was generated (Young and Neher, 2009) with an expression
cassette consisting of the synthetic intron from pCI (Promega), the
neuron-specific human synapsin-1 promoter (Ku¨gler et al., 2001), a
multiple cloning site, and the SV40 polyadenylation signal. Codon-
optimized WT and G2019S human LRRK2 cDNAs with three tandem
FLAG tags at the N terminus were provided by Dr. Christopher Ross
(JohnsHopkins University, Baltimore,MD). Each cDNAwas cloned in a
two-step procedure into the multiple cloning site of the pDC511 shuttle
plasmid, making use of a unique HindIII restriction site within the
LRRK2 sequence. A pDC511-GFP plasmid was also generated. A modi-
fied version of the FLP, frt human Ad5 genomic plasmid (Microbix)
and each pDC511 shuttle plasmid were cotransfected into E2a-
complementing cells (E2T), and rAd virus production was performed
according to standard protocol (Ng and Graham, 2002). Vector stocks
were amplified from plaque isolates to guarantee homogeneity of the
production. Final vector stocks were purified and concentrated using the
Vivapure AdenoPACK 100RT kit (Sartorius). Viral titers of purified vec-
tor stocks were determined byOD260measurements. The following titers
were obtained, expressed as viral particles (vp)/l: 2.9  109 vp/l for
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rAd-GFP, 2.3  109 vp/l for rAd-LRRK2-
WT, and 2.6  109 vp/l for rAd-
LRRK2-G2019S.
Stereotaxic unilateral injection into the
striatum of rats
Adult Wistar female rats (Charles River Labo-
ratories) weighing200 g were housed in 12 h
light/dark cycle, with ad libitum access to food
and water, in accordance with the Swiss legis-
lation and the European Community Council
directive (86/609/EEC) for the care and use of
laboratory animals. For stereotaxic injections,
the animals were deeply anesthetized with a
mixture of xylazine/ketamine and placed in the
stereotaxic frame (David Kopf Instruments).
Recombinant Ad vectors were injected unilat-
erally in the striatum at six points, correspond-
ing to two deposits along three needle tracts at
the following anterior–posterior, mediolateral
relative to bregma, dorsoventral relative to
skull surface coordinates: 0.48/2.4/4.8 and
6.0; 0.48/3.2/4.8 and 6.0; 0.48/4.0/
4.8 and 6.0. Two microliters of virus at a
concentration of 2.3 109 vp/l were injected
per site using a 10 l Hamilton syringe with a
34 gauge blunt tip needle at a speed of 0.2 l/
min, with an automatic pump (CMAMicrodi-
alysis). The more ventral site in each needle
tract was injected first and the needle was left
in place for 2 min before slowly moving to
the more dorsal site in the same needle tract,
after injection of which the needle was left
for an additional 5 min before slowly being
withdrawn.
Western blot analysis
Quantification of FLAG-LRRK2 expression lev-
els. HEK 293T cells were infected with 3.2 
109 vp of rAd-LRRK2-WT or rAd-LRRK2-
G2019S (n  3 per group) and harvested 48 h
after infection in Triton extraction buffer (50
mM Tris-HCl, pH 7.5, 150 mM NaCl, 2 mM
EDTA, and 1% Triton X-100) containing pro-
tease inhibitors (Roche Applied Science). rAd-
LRRK2-WT- and rAd-LRRK2-G2019S-injected
rats were killed at 10 d after injection (n 4 per
group). The SN and striata from injected and
uninjected hemispheres were then rapidly dis-
sected and homogenized in Triton extraction
buffer containing protease inhibitors (Roche
Applied Science). Western blot analysis on 50
g of protein was performed with a mouse
monoclonal antibody against FLAG (mouse
IgG, 1:1000; Anti-FLAG M2, Sigma) and an anti-actin antibody to con-
firm equal protein loading (goat IgG, 1:1000; sc-1616, Santa Cruz Bio-
technology). Detection and quantification were performed using the
Odyssey Infrared Imaging System.
Soluble LRRK2 extraction and native PAGE/SDS-PAGE analysis. rAd-
LRRK2-WT and rAd-LRRK2-G2019S-injected rats were killed at 14 d
after injection (n  4 per group). The SN and striata from injected and
uninjected hemispheres were then rapidly dissected and homogenized in
100 l of 50 mM HEPES, pH 7.4, containing protease and phosphatase
inhibitors (Roche Applied Science). Lysates were centrifuged at
175,000  g, and protein content in supernatants was determined by a
BCA assay (Pierce). A fraction of the soluble extracts were combinedwith
4 reducing sample buffer (150 mM Tris-HCl, pH 7.0, 12% SDS, 6%
-mercaptoethanol, 30% glycerol, and 0.05% Coomassie Blue G-250)
for SDS-PAGE analysis. Sixty micrograms of protein were loaded for
each sample. The remaining fraction was used for loading on 4–16%
bis-tris blue native polyacrylamide gels (Invitrogen) followed by over-
night transfer to PVDF membranes. Equivalent sample volumes were
loaded corresponding to100g of protein for striatal extracts and90
g of protein for nigral extracts. Detection was performed using en-
hanced chemiluminescence (GEHealthcare). Antibodies used were anti-
FLAG-HRP (1:2000, mouse IgG; A 8592, Sigma) and anti-actin and
rabbit monoclonal anti-LRRK2 (1:2000, c41–2/MJFF-2, kindly provided
by the Michael J. Fox Foundation), which recognizes both rodent and
human LRRK2. Densitometric analysis was performed using the NIH
ImageJ software.
Immunohistological analysis and quantification
Tissue processing. For histological analysis, animals were killed at 10, 21,
and 42 d after injection. n 5/group/time point except n 4 for G2019S
at 21 d (rat number 5 in this group was not included due to a technical
Figure 1. Comparable expression and oligomerization of WT and mutant G2019S LRRK2. A, Western blot analysis of FLAG-
LRRK2 expression. HEK 293T cells were infected with an equal amount of viral particles of rAd-WT-LRRK2 or rAd-G2019S-LRRK2
(n 3 per group). A noninfected (NI) control was included. rAd-WT-LRRK2- and rAd-G2019S-LRRK2-injected animals were killed
at 10 d after injection (n 4 per group). Protein extracts from each sample were subjected to SDS gel electrophoresis and
membranes were probed with anti-FLAG and anti-actin antibodies. Both vectors were found to drive equivalent levels of expres-
sion of FLAG-LRRK2 in vitro and in vivo, following densitometric analysis and normalization to actin levels. B, Fold human LRRK2
overexpression in the SN. rAd-WT-LRRK2- and rAd-G2019S-LRRK2-injected animals were killed at 14 d after injection (n 4 per
group). Protein extracts from uninjected () and injected () SN were separated by SDS gel electrophoresis. Membranes were
probed with an anti-LRRK2 antibody that recognizes rodent and human LRRK2. The fold overexpression of human LRRK2 in each
individual rat was estimated by comparing LRRK2 signal intensities, normalized to actin, between the uninjected and injected SN.
Further probing of themembranewith anti-FLAG antibody confirmed the rAd-driven expression of FLAG-LRRK2 in all injected SN.
An average twofold overexpression of human LRRK2wasmeasured for both theWT andG2019S groups. C, Native PAGE analysis of
endogenous and overexpressed human LRRK2. A fraction of the soluble protein extracts of dissected striata and SNwere analyzed
by native PAGE. Upon staining with an anti-LRRK2 antibody, endogenous LRRK2 in the striatum and SN was shown to assemble
intohigh-molecular-weight complexes ranging from480kDa to1MDa.Despite loadingup to100gof total proteins,we could
not detect anyproteinmigrating at the size expected formonomeric LRRK2neither in the SN, nor in striatal extracts. Overexpressed
WTandG2019SLRRK2, detectedbyanti-FLAG immunostaining, showedaqualitatively similar higher-orderdistribution compared
to each other and endogenous LRRK2. Uninjected striatal and nigral extracts were loaded as controls for the specificity of the
anti-FLAG signal. Despite thepresenceof anonspecific bandat720kDauponFLAGstainingonSN lysates,we could clearly detect
higher-order complexes between 480 and 720 kDa for overexpressed LRRK2 in the SN.
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problem during injection). Rats were deeply anesthetized by an overdose
of pentobarbital and perfused transcardially first with PBS and then with
ice-cold 4% paraformaldehyde (PFA). Brains were kept for 90min in 4%
PFA and then transferred into 25% sucrose. Twenty-five-micrometer-
thick coronal sections were harvested on a sliding microtome (SM2400;
Leica) at the temperature of 20°C. Slices were then processed for im-
munohistological treatment.
Immunohistochemistry. Primary antibodies used in this study were
anti-tyrosine hydroxylase (TH) (rabbit IgG, 1:500; AB152, Millipore
Bioscience Research Reagents), anti-GFP (mouse IgG 1:500; A-11120,
Invitrogen), anti-FLAG (mouse IgG 1:500; M2 F1804, Sigma), anti-
VMAT2 (rabbit IgG, 1:2000; AB1767, Millipore Bioscience Research
Reagents), anti-ubiquitin (rabbit IgG, 1:1000; Z0458, Dako), anti--
synuclein (mouse IgG, 1:100; Syn-1, BD Biosciences), anti-pS129--
synuclein (mouse IgG, 1:500; pSyn#64, Wako), anti-Iba1 (rabbit IgG,
1:500; 019-19741,Wako), anti-GFAP (mouse IgG, 1:800; G3893, Sigma),
and anti-PHF-TauAT8 (mouse IgG, 1:100,MN1020, AT8 clone, Pierce).
For double-fluorescence labeling, we used secondary antibodies conjugated
to Alexa Fluor-488 (Invitrogen) and Cy3 (Jackson ImmunoResearch). For
bright-field microscopy, we used biotinylated
goat anti-rabbit or anti-mouse secondary anti-
bodies (1:200; Vector Laboratories).
Stereological quantification of TH-positive
neurons. Unbiased stereological estimation of
the number of TH-positive neurons was per-
formed according to the optical fractionator
method using the Stereo Investigator Software
(MBF Bioscience). Optical dissector grids of
40  40 m were placed in a systematic ran-
dom manner 100 100 m apart and offset 2
m from the surface of the section. Gundersen
error coefficients of 0.10 were accepted. Ev-
ery eighth section covering the entire extent of
the SNpc was included in the counting proce-
dure. Results were expressed as a percentage
loss with respect to the uninjected side. Analy-
ses were performed in a blinded fashion.
Striatal optical density measurement. Striatal
dopaminergic innervation at 21 and 42 d was
quantified by measuring the optical density
(OD) of TH-immunoreactive terminals in 24
coronal sections (one in six sections) through-
out the entire striatum. These sections were
scanned using Nikon Super Coolscan 4000
scanner, and the OD of the tissue was analyzed
using the NIH ImageJ software.
Statistical analysis
For comparisons between rAd-GFP, rAd-WT-
LRRK2, and rAd-G2019S-LRRK2, one-way
ANOVAs were performed for each time point
(Statistica, Statsoft). Significance was set when
p 0.05. Data represent mean SEM.
Results
High-titer recombinant second-generation
human serotype 5 adenoviral (rAd) vectors
(Zhou and Beaudet, 2000; Young and Ne-
her, 2009)witha sufficiently largepackaging
capacity for the full-length LRRK2 cDNA
(7.6 kb) were generated, encoding GFP,
or FLAG-tagged WT or G2019S human
LRRK2. Since LRRK2 is predominantly lo-
calized to neurons in the mammalian brain
(Biskup et al., 2006), the neuronal-specific
human synapsin-1 promoter (Ku¨gler et al.,
2001)was chosen to drive transgene expres-
sion from rAd vectors. Direct injections of
rAd in the SNpc results in poor transduction of dopaminergic neu-
rons (Lewis et al., 2010). In contrast, adenoviral particles can be
efficiently retrogradely transported todopaminergic neuronswithin
the SNpc following intrastriatal injections (Ku¨gler et al., 2003).
Upon injection of a rAd-GFP vector at six different sites (2 l per
site) in the striatum of adult rats (supplemental Fig. 1A, available at
www.jneurosci.org as supplemental material), we observed a
widespread distribution of rAd-GFP around the injection sites
at 10 d after injection (supplemental Fig. 1B, available at www.
jneurosci.org as supplemental material), resulting in efficient
retrograde transport and robust GFP expression in 31 3.6%
(n  4) of nigral dopaminergic neurons across the entire
length of the SNpc (supplemental Fig. 1C, available at www.
jneurosci.org as supplemental material), with no visible signs
of inflammation in the SNpc (as confirmed by Nissl staining
for cellular infiltrations, data not shown).
Figure 2. Robust and persistent rAd-driven transgene expression in the SNpc over time. A, Representative photomicrographs
showing GFP and LRRK2 overexpression, revealed by anti-GFP and anti-FLAG immunostaining, respectively, in retrogradely trans-
duced neurons of the SNpc of animals killed at 10, 21, and 42 d after injection. All animals at each time point displayed robust
transgeneexpression.B, High-magnificationphotomicrographs of anti-FLAG immunostainings in the SNpcof rAd-WT-LRRK2- and
rAd-G2019S-LRRK2-injected animals at 10 d. Overexpressed LRRK2 localized to the cytoplasmandneuritic processes of transduced
nigral neurons. No visible differences in cellular localization were observed between the wild-type and mutant form of overex-
pressed LRRK2. Scale bars: A, 200m; B, 50m.
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rAd-WT-LRRK2 and rAd-G2019S-LRRK2 vectors were
shown to drive equivalent levels of expression of LRRK2 in vitro
inHEK-293T cells and in vivo in the SNpc and striatum following
intrastriatal injections of rats, as described above for rAd-GFP
(Fig. 1A). Human LRRK2 is expressed on average at twofold the
levels of endogenous LRRK2 as determined from nigral tissue
homogenates of injected rats from both WT and G2019S groups
(Fig. 1B). With only 30% of nigral dopaminergic neurons actu-
ally transduced, this finding suggests that high levels of overex-
pression are achieved in each individual neuron. We further
confirmed that human LRRK2 is expressed as an intact full-length
protein in vivo by analysis of anti-FLAG immunoprecipitates de-
rived from striatal extracts of rats injected with rAd-WT-LRRK2
and rAd-G2019S-LRRK2 vectors (supplemental Fig. 2, available
at www.jneurosci.org as supplemental material). Finally, we
demonstrate by native PAGE that endogenous LRRK2 in striatal
and nigral extracts assembles into high-molecular-weight com-
plexes ranging from 420 kDa to 1 MDa (Fig. 1C). Overex-
pressedWT andG2019S LRRK2 in the striatum and SNpc adopts
similar higher-order structures with no obvious difference be-
tween LRRK2 variants (Fig. 1C). In native gel conditions, despite
loading up to 100 g of total proteins, we could not detect any
protein migrating at the size expected for monomeric LRRK2,
suggesting that LRRK2 exists predominantly within high-
molecular-weight complexes.
Injected animals display robust overexpression of LRRK2 in
retrogradely transduced nigral neurons, persisting up to 42 d
after injection despite a progressive decline in expression levels
over time (Fig. 2A). As previously reported for first-generation
rAd vectors, the observed decline in transgene expression is most
likely due to a loss of adenoviral vector genomes in transduced
cells (Ku¨gler et al., 2003), since no cell loss is detected in the
rAd-GFP and rAd-WT-LRRK2 groups at 42 d (Fig. 3B). No vis-
ible differences in subcellular localization are observed between
WT and G2019S LRRK2 (Fig. 2B). Indeed, both forms of the
protein localize to the cytoplasm and proximal neuritic processes
of nigral dopaminergic neurons, consistent with the expression
pattern of endogenous LRRK2 in the SNpc in rodent and human
brain (Biskup et al., 2006).
Stereological quantification of the number of dopaminergic
neurons in the SNpc was performed at 10, 21, and 42 d after
injection. No cell loss is detected in the rAd-GFP- and rAd-WT-
LRRK2-injected groups. In contrast, overexpression of G2019S
LRRK2 causes a progressive loss of TH-positive dopaminergic
neurons in the SNpc, reaching 21.3 2.2%at 42 d (Fig. 3A,B). At
the same time point, a similar loss of neurons is observed using a
second dopaminergic marker, VMAT2 (Fig. 3A,B). Quantifica-
tion of total Nissl-positive neurons in the SNpc confirms that
LRRK2G2019S causes neuronal cell loss rather than a phenotypic
loss of dopaminergic markers (Fig. 3A,B). In the injected stria-
tum, the presence of an inflammatory reaction around the needle
tracts at 10 d precludes immunostaining at this time point. As of
21 d, however, the inflammation resolves, and an average 10%
decrease in striatal TH-positive fiber density, as determined by
striatal OD measurement, is measured for all groups at 21 and
42 d after injection (supplemental Fig. 3, available at www.
jneurosci.org as supplemental material). We do not observe an
increased denervation in rAd-G2019S-LRRK2-injected animals
relative to theWT-LRRK2 and GFP groups. This may be due to a
compensatory sprouting of nigrostriatal projections from the re-
maining dopaminergic neurons.
Next, we explored the pathological alterations associated with
neuronal degeneration due to G2019S LRRK2 overexpression.
We do not detect abnormal accumulation or aggregation of
-synuclein and ubiquitin in dopaminergic neurons of the in-
jected SNpc in either group up to 42 d (supplemental Fig. 4,
available at www.jneurosci.org as supplemental material). Nor
does LRRK2 overexpression lead to any increase in endogenous
Figure 3. Mutant G2019S LRRK2 causes a loss of nigral dopaminergic neurons.A, Represen-
tative photomicrographs showing the loss of TH and VMAT2 neurons in the SNpc of rAd-
G2019S-LRRK2-injected animals at 42 d, as revealed by TH and VMAT2 immunohistochemistry.
VMAT2-labeled sectionswere counterstainedwith Nissl to confirm neuronal cell loss. Scale bar,
200 m. The higher-magnification inset (scale bar, 20 m) shows VMAT2/Nissl nigral
neurons, indicated by arrowheads, and Nissl nigral neurons, which do not express VMAT2,
indicated by arrows. B, Stereological quantification of the percentage loss of TH, VMAT2,
andNisslneurons in the SNpcof rAd-GFP-, rAd-WT-LRRK2-, and rAd-G2019S-LRRK2-injected
animals (n 5/group/time point, except n 4 for the G2019S group at 21 d). No significant
loss of nigral neuronswas detected in theGFP andWT LRRK2groups. In contrast, G2019S LRRK2
causedaprogressive loss of THneuronsbetween10and42d.Neuronal losswas confirmedby
quantificationofVMAT2andNisslnigral neurons at 42d.One-wayANOVAstatistics for the
loss of TH nigral neurons at 10 d, F(2,12) 4.96; 21 d, F(2,11) 6.82; and 42 d, F(2,12) 8.66;
for the loss of VMAT2 nigral neurons at 42 d, F(2,12) 6.44; for the loss of Nissl nigral
neurons at 42 d, F(2,12) 7.88. Newman–Keuls post hoc analyses showed significant differ-
ences between the G2019S-LRRK2 and GFP groups (*p 0.05, **p 0.01), and the G2019S-
LRRK2 and WT-LRRK2 groups ( #p 0.05, ##p 0.01). There were no significant differences
between the GFP andWT-LRRK2 groups. Bars represent the mean SEM.
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-synuclein phosphorylation at residue serine 129 (supplemental
Fig. 4, available at www.jneurosci.org as supplemental material).
However, immunostaining for the pathological phospho-tau
epitope (pSer202/pThr205) with the AT8 antibody reveals ab-
normal hyperphosphorylation of tau in dystrophic nigral neuritic
processes uponWT and G2019S LRRK2 overexpression, but not
GFP, at 10 d after injection (Fig. 4). AT8-positive immunostain-
ing is no longer visible at 21 d after injection (supplemental Fig. 5,
available at www.jneurosci.org as supplemental material), sug-
gesting a transient appearance correlating with maximal expres-
sion of WT or G2019S human LRRK2, but not correlating with
neuronal cell death, present only with G2019S LRRK2 transduc-
tion.We do not detect any AT8-immunopositive processes in the
striatum at 21 d (supplemental Fig. 5, available at www.jneurosci.
org as supplemental material). When compared to the GFP-
expressing animals, eitherWTorG2019S LRRK2 expression does
not lead to increased recruitment and activation ofmicroglia and
astrocytes asmeasured by Iba1 andGFAP immunostaining in the
striatum and SNpc (data not shown).
Discussion
Adenoviral vectors provide an efficient answer to the size con-
straints of the LRRK2 coding sequence (7.6 kb) and represent
highly flexible tools for the study of mutant LRRK2 pathogenesis
in the SNpc of adult rats. By introducing an abrupt change in
LRRK2 expression in the adult brain, we induce a robust and
rapidly progressing nigral neurodegeneration. This technology
also enables direct comparisons between the wild-type and G2019S
variants of LRRK2, allowing us to unambiguously establish that
LRRK2 causes progressive nigral neurodegeneration only in the
presence of the G2019Smutation.
Existing LRRK2 transgenic mice, in contrast, do not display
nigral cell loss and likely represent models of early functional
impairments and pathogenic events arising from PD-associated
mutations in LRRK2 (Li et al., 2009, 2010;
Lin et al., 2009; Tong et al., 2009; Melrose
et al., 2010). The difference in phenotype
with the present model may be explained
by higher levels of LRRK2 expression
achieved with viral vectors. Compensa-
tory mechanisms may also have been ac-
tivated in transgenic mice, linked to the
onset of expression during development.
Nigral neurodegeneration induced by
G2019S LRRK2 was also recently demon-
strated in mice, using HSV amplicon as a
gene transfer tool (Lee et al., 2010), fur-
ther supporting the use of viral vectors to
model LRRK2 pathology in rodents.
In summary, we have generated a new
rat model of PD, based on the most com-
mon PD-associated mutation in LRRK2,
which recapitulates one of the cardinal
pathological features of the disease. We
believe this viral gene-transfer model will
be a highly valuable tool for the in vivo
evaluation of neuroprotective therapies
for both familial and sporadic PD.
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